Caredx, Inc. insider trading
Every open-market purchase and sale by Caredx, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Caredx, Inc.’s insiders pay?
From January 15, 2015 to August 6, 2026, 17 insiders reported 31 open-market purchases and 41 sales not made under a pre-set plan in Caredx, Inc. Twelve months after each purchase was reported, the shares were −1.1% against the S&P 500 on average (median −22.4%), over 19 purchases with a full year of prices; 11% beat the index. After sales, the shares moved +1.8% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on January 16, 2015 into $10,457 by November 2, 2026, +0.4% a year. It held shares 32% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $13,463 (+2.6% a year), and held throughout $45,534 (+13.8%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Gagnon Neil | 10% owner | 26 | +5.8% (17) | 12% | 1 | −38.6% (1) | November 2, 2018 |
| Hagstrom William A | Director | 0 | — | — | 8 | +12.1% (8) | June 13, 2025 |
| Bickerstaff George | Director | 0 | — | — | 7 | −32.6% (6) | August 6, 2026 |
| Goldberg Michael | Director | 0 | — | — | 5 | −23.1% (4) | August 6, 2026 |
| Maag Peter | Executive Chair | 1 | — | — | 4 | −19.5% (4) | August 22, 2024 |
| Colon Grace | Director | 0 | — | — | 3 | −66.3% (3) | August 11, 2022 |
| Nelles Mitchell J | Chief Operating Officer | 1 | — | — | 2 | +233.4% (2) | July 3, 2018 |
| Cournoyer Christine | Director | 0 | — | — | 2 | +4.2% (2) | May 14, 2025 |
| Johnson Alexander L | See Remarks | 0 | — | — | 2 | −75.2% (2) | August 22, 2024 |
| Snyderman Ralph | Director | 0 | — | — | 2 | −74.1% (2) | June 10, 2021 |
| Torres Arthur A | Director | 1 | −58.7% (1) | 0% | 1 | — | May 18, 2026 |
| Bell Michael Brian | Chief Financial Officer | 0 | — | — | 1 | +35.6% (1) | August 14, 2018 |
| Dhingra Ankur | Chief Financial Officer | 1 | −60.8% (1) | 0% | 0 | — | November 29, 2021 |
| King Sasha | Chief Commercial Officer | 0 | — | — | 1 | +107.6% (1) | August 1, 2018 |
| Novack Jeffrey Adam | Secretary and General Counsel | 0 | — | — | 1 | −38.2% (1) | April 9, 2025 |
| Whitson Todd | Chief Commercial Officer | 1 | — | — | 0 | — | October 4, 2016 |
| Yee James P | Chief Medical Officer | 0 | — | — | 1 | +293.6% (1) | December 8, 2017 |
When several insiders traded Caredx, Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Caredx, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 1 buying crowd with six months of prices, it averaged −31.6% against the index. After 5 selling crowds, +4.7%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| May 30, 2025 | 3 selling | −29.4% | −11.4% | −0.5% |
| November 30, 2021 | 2 buying | −10.4% | −31.6% | −60.8% |
| May 28, 2021 | 4 selling | −8.3% | −57.3% | −67.6% |
| December 31, 2020 | 3 selling | −7.3% | +7.4% | −66.0% |
| May 29, 2020 | 4 selling | −8.7% | +54.4% | +110.1% |
| August 31, 2018 | 3 selling | +25.0% | +30.6% | −11.6% |